Guardant Health, Inc. (NASDAQ:GH) CEO Amirali Talasaz Sells 1,680 Shares

Guardant Health, Inc. (NASDAQ:GH) CEO Amirali Talasaz sold 1,680 shares of the stock in a transaction that occurred on Thursday, June 5th. The stock was sold at an average price of $50.00, for a total value of $84,000.00. Following the transaction, the chief executive officer now owns 2,187,060 shares in the company, valued at approximately $109,353,000. This trade represents a 0.08% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Amirali Talasaz also recently made the following trade(s):

• On Monday, June 9th, Amirali Talasaz sold 77,853 shares of Guardant Health stock. The stock was sold at an average price of $50.09, for a total value of $3,899,656.77.
• On Friday, June 6th, Amirali Talasaz sold 39,751 shares of Guardant Health stock. The stock was sold at an average price of $50.07, for a total value of $1,990,332.57.
• On Thursday, May 1st, Amirali Talasaz sold 106,784 shares of Guardant Health stock. The stock was sold at an average price of $49.01, for a total value of $5,233,483.84.

Guardant Health Stock Up 3.1%

Shares of GH stock traded up $1.47 during trading hours on Monday, reaching $49.53. The company’s stock had a trading volume of 2,926,769 shares, compared to its average volume of 2,130,739. The firm’s 50 day simple moving average is $43.05 and its 200-day simple moving average is $41.25. The company has a market capitalization of $6.14 billion, a price-to-earnings ratio of -13.91 and a beta of 1.37. Guardant Health, Inc. has a fifty-two week low of $20.14 and a fifty-two week high of $52.92.

Guardant Health (NASDAQ:GH) last issued its earnings results on Wednesday, April 30th. The company reported ($0.49) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.08. The firm had revenue of $203.47 million for the quarter, compared to the consensus estimate of $189.91 million. Guardant Health had a negative return on equity of 19,157.20% and a negative net margin of 59.05%. The company’s revenue was up 20.8% compared to the same quarter last year. During the same quarter last year, the business posted ($0.46) EPS. Sell-side analysts predict that Guardant Health, Inc. will post -2.9 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the company. Piper Sandler reiterated an “overweight” rating and set a $60.00 target price (up previously from $50.00) on shares of Guardant Health in a research note on Tuesday, May 6th. JPMorgan Chase & Co. increased their target price on Guardant Health from $50.00 to $55.00 and gave the stock an “overweight” rating in a research note on Friday, February 21st. Stephens reiterated an “overweight” rating and set a $55.00 target price on shares of Guardant Health in a research note on Wednesday, March 26th. Scotiabank restated an “outperform” rating on shares of Guardant Health in a research note on Monday, May 5th. Finally, UBS Group raised their price objective on Guardant Health from $65.00 to $70.00 and gave the stock a “buy” rating in a research note on Thursday, May 1st. Twenty equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $53.29.

Institutional Investors Weigh In On Guardant Health

Several hedge funds have recently modified their holdings of the company. SBI Securities Co. Ltd. acquired a new position in Guardant Health during the 4th quarter worth about $43,000. SVB Wealth LLC acquired a new position in Guardant Health during the 1st quarter worth about $54,000. Kimelman & Baird LLC acquired a new position in Guardant Health during the 4th quarter worth about $58,000. NewEdge Advisors LLC lifted its holdings in Guardant Health by 13.5% during the 4th quarter. NewEdge Advisors LLC now owns 1,929 shares of the company’s stock worth $59,000 after buying an additional 230 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in Guardant Health during the 4th quarter worth about $61,000. Institutional investors and hedge funds own 92.60% of the company’s stock.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.